TAS-119
TAS-119 is a potent, selective and orally active Aurora A inhibitor with an IC50 of 1.0 nM. TAS-119 shows high selectivity for Aurora A over other protein kinases, including Aurora B (IC50 of 95 nM) . TAS-119 has potent antitumor activites[1].
Product Specifications
CAS Number
[1453099-83-6]
UNSPSC
12352005
Target
Aurora Kinase
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tas-119.html
Purity
98.01
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(C1(CC2=NC(NC3=NNC(C)=C3)=C(F)C=C2)CCN(C(C4=CC=CC(Cl)=C4Cl)=O)CC1)O
Molecular Formula
C23H22Cl2FN5O3
Molecular Weight
506.36
References & Citations
[1]Hiroshi Sootome, et al. Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design. Mol Cancer Ther. 2020 Oct;19 (10) :1981-1991.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
Aurora A; Aurora B
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
C8376-25E-ML490 100 µL
CXCR7, CT (G-protein Coupled Receptor 159, Chemokine Orphan Receptor 1, G-protein Coupled Receptor RDC1 Homolog, RDC-1, C-X-C Chemokine Receptor Type 7, CXC-R7, CXCR-7, CMKOR1, GPR159, RDC1) (MaxLight 490) discontinued
Ask
View Details